(1S)-tert-butoxycarbonylamino-4-methylindan-5-carboxylic acid | 903557-91-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (1S)-tert-butoxycarbonylamino-4-methylindan-5-carboxylic acid
• 英文别名: (1S)-4-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1H-indene-5-carboxylic acid
• CAS: 903557-91-5
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: HLXYLHQWDMKWTL-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1S)-tert-butoxycarbonylamino-4-methylindan-5-carboxylic acid 、 3-溴丙烯 在 lithium hydroxide 、 四丁基硫酸氢铵 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 以99%的产率得到prop-2-enyl (1S)-4-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1H-indene-5-carboxylate
  参考文献：
  名称：

  WO2008/63671

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl (1S)-4-methyl-1-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1H-indene-5-carboxylate 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (1S)-tert-butoxycarbonylamino-4-methylindan-5-carboxylic acid
  参考文献：
  名称：

  Metalloprotease inhibitors

  摘要：

  本发明涉及具有含芳香族MMP抑制化合物的酰胺，其具有单酰胺杂芳基团，化学式I和II：

  公开号：

  US20080021024A1

文献信息

• Multicyclic bis-amide MMP inhibitors
  申请人：Powers Timothy

  公开号：US20060173183A1

  公开（公告）日：2006-08-03

  The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。
• Heterobicyclic metalloprotease inhibitors
  申请人：Gallagher M. Brian

  公开号：US20070155737A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic ADAMTS-4 inhibiting compounds.

  本发明通常涉及含有酰胺基团的药物，特别是含有酰胺基团的杂双环金属蛋白酶抑制剂化合物。更具体地，本发明提供了一类新的杂双环ADAMTS-4抑制剂化合物。
• WO2006/128184
  申请人：——

  公开号：——

  公开（公告）日：——
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.